Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 15/20 | 0.74 |
| ▸ | AR | P10275 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3385194 | 0.86 | PARP1 (1.00) | PARP1ARCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3385186 | 0.78 | PARP1 (0.80) | PARP1ARCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3385131 | 0.77 | PARP1 (0.82) | PARP1ARCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3388667 | 0.77 | PARP1 (0.78) | PARP1ARCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3389677 | 0.76 | PARP1 (1.00) | PARP1ARCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3387621 | 0.75 | PARP1 (0.76) | PARP1ARLMNA | |
| SCHEMBL3388053 | 0.73 | PARP1 (0.72) | PARP1ARCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5151001 | 0.73 | KDM4E (0.71) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL31259847 | 0.73 | KDM4E (0.71) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL3383204 | 0.72 | PARP1 (0.71) | PARP1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501822-B1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARM LTD (GB) | 2010-12-15 | — | — | EP | disclosed |
| EP-1501822-B1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARM LTD (GB) | 2010-12-15 | — | — | EP | disclosed |
| US-7196085-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| US-7196085-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| US-7196085-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| EP-1501822-A1 | PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Limited (GB) | 2005-02-02 | — | — | EP | disclosed |
| US-20040023968-A1 | Phthalazinone derivatives, and their use as pharmaceuticals. In particular, the present as enzyme inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2004-02-05 | — | — | US | disclosed |
| WO-2003093261-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023968-A1 | Phthalazinone derivatives, and their use as pharmaceuticals. In particular, the present as enzyme inhibitors | PARP1, PARP2, PARP15 | PARP1 1/4885AR 758/4885CA12 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.